Literature DB >> 22215326

Recurrent salivary gland cancer.

M Boyd Gillespie1, W Greer Albergotti, David W Eisele.   

Abstract

OPINION STATEMENT: Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.

Entities:  

Mesh:

Year:  2012        PMID: 22215326     DOI: 10.1007/s11864-011-0174-0

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  31 in total

Review 1.  MR imaging of salivary glands.

Authors:  Gaurang V Shah
Journal:  Magn Reson Imaging Clin N Am       Date:  2002-11       Impact factor: 2.266

2.  The impact of second opinion surgical pathology on the practice of head and neck surgery: a decade experience at a large referral hospital.

Authors:  William H Westra; Joseph D Kronz; David W Eisele
Journal:  Head Neck       Date:  2002-07       Impact factor: 3.147

3.  Chemoreirradiation for recurrent salivary gland malignancies.

Authors:  Aaron W Pederson; Daniel J Haraf; Elizabeth A Blair; Kerstin M Stenson; Mary-Ellyn Witt; Everett E Vokes; Joseph K Salama
Journal:  Radiother Oncol       Date:  2010-04-10       Impact factor: 6.280

4.  Expression and mutations of p53 in salivary gland tumours.

Authors:  V J Kärjä; K J Syrjänen; A K Kurvinen; S M Syrjänen
Journal:  J Oral Pathol Med       Date:  1997-05       Impact factor: 4.253

5.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

6.  Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas.

Authors:  F V Mariano; S D da Silva; T C Chulan; O P de Almeida; L P Kowalski
Journal:  Int J Oral Maxillofac Surg       Date:  2011-01-19       Impact factor: 2.789

7.  Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma.

Authors:  Scott M Kaszuba; Mark E Zafereo; David I Rosenthal; Adel K El-Naggar; Randal S Weber
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-06

Review 8.  Imaging of salivary gland tumours.

Authors:  Y Y P Lee; K T Wong; A D King; A T Ahuja
Journal:  Eur J Radiol       Date:  2008-03-11       Impact factor: 3.528

9.  Recurrent cancer of the parotid gland: how well does salvage surgery work for locoregional failure?

Authors:  Kenya Kobayashi; Kazunari Nakao; Masafumi Yoshida; Mizuo Ando; Yasuhiro Ebihara; Takahiro Asakage; Tatsuya Yamasoba
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2009-09-09       Impact factor: 1.538

10.  Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.

Authors:  Robert Haddad; A Dimitrios Colevas; Jeffrey F Krane; Dennis Cooper; Bonnie Glisson; Philip C Amrein; Linda Weeks; Rosemary Costello; Marshall Posner
Journal:  Oral Oncol       Date:  2003-10       Impact factor: 5.337

View more
  12 in total

1.  EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells.

Authors:  Yang Wang; Jingzhou Hu; Yan'an Wang; Weimin Ye; Xiangkai Zhang; Houyu Ju; Dongliang Xu; Liu Liu; Dongxia Ye; Ling Zhang; Dongwang Zhu; Jiong Deng; Zhiyuan Zhang; Shuli Liu
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

Review 2.  Genetic alterations in salivary gland cancers.

Authors:  Linda X Yin; Patrick K Ha
Journal:  Cancer       Date:  2016-02-29       Impact factor: 6.860

Review 3.  Salivary gland stem cells: A review of development, regeneration and cancer.

Authors:  Elaine Emmerson; Sarah M Knox
Journal:  Genesis       Date:  2018-05-04       Impact factor: 2.487

Review 4.  Salivary gland cancer stem cells.

Authors:  April Adams; Kristy Warner; Jacques E Nör
Journal:  Oral Oncol       Date:  2013-06-28       Impact factor: 5.337

Review 5.  Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Vincent Vander Poorten; Missak Haigentz; Johannes A Langendijk; Remco de Bree; Michael L Hinni; William M Mendenhall; Vinidh Paleri; Alessandra Rinaldo; Jochen A Werner; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-26       Impact factor: 2.503

6.  Recurrent parotid gland carcinoma: how effective is salvage surgery?

Authors:  Lluís Nisa; Urs Borner; Cilgia Dür; Andreas Arnold; Roland Giger
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-01       Impact factor: 2.503

7.  Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.

Authors:  Maria M Szwarc; Ramakrishna Kommagani; Allison P Jacob; William C Dougall; Michael M Ittmann; John P Lydon
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

8.  Cytomegalovirus-induced salivary gland pathology: resistance to kinase inhibitors of the upregulated host cell EGFR/ERK pathway is associated with CMV-dependent stromal overexpression of IL-6 and fibronectin.

Authors:  Michael Melnick; Parish P Sedghizadeh; Krysta A Deluca; Tina Jaskoll
Journal:  Herpesviridae       Date:  2013-01-23

9.  Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.

Authors:  Daiki Mochizuki; April Adams; Kristy A Warner; Zhaocheng Zhang; Alexander T Pearson; Kiyoshi Misawa; Scott A McLean; Gregory T Wolf; Jacques E Nör
Journal:  Oncotarget       Date:  2015-09-08

10.  Oncocytoma of the parotid gland: a case report and review of the literature.

Authors:  Ilson Sepúlveda; Enrique Platín; M Loreto Spencer; Pablo Mucientes; Michael Frelinghuysen; Pablo Ortega; David Ulloa
Journal:  Case Rep Oncol       Date:  2014-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.